



Dkt. 50659/JPW/JML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

David Baltimore, et al.

Serial No.

08/813,323

Filed

March 10, 1997

Art Unit: 1815

For

TRUNCATED CRAF1 INHIBITS CD40 SIGNALING

1185 Avenue of the Americas New York, New York 10036

July 30, 1997

Assistant Commissioner for Patents

Washington, D.C. 20231

ATTENTION: BOX SEQUENCE

SIR:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same content as that submitted on pages 40-48 entitled "Sequence Listing," attached hereto as Exhibit C.

David Baltimore, et al. U.S. Serial No.: 08/813,323 Filed: March 10, 1997 Page 2

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

AL SALES OF THE SECOND SECOND

Jane M. Love

c/o Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036

(212) 278-0400

32	4_	}	
9	1997	15	Application No.:
1.8	PADENTE	FIC	E TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
•	MI	ICL	FOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.		
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
X	´3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
	7.	Other:		
Applicant Must Provide:				
X	Ar	n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".		
		າ initial or substitute paper ເດລy of the "Sequence Listing", as well as an amendment directing its try into the specification.		
X	ар	statement that the content of the paper and computer readable copies are the same and, where plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).		

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE